Cases & Deals

Resonant Therapeutics enters into target discovery and therapeutic validation collaboration agreement with Janssen

Clients Resonant Therapeutics, Inc.

Jones Day represented Resonant Therapeutics, Inc. in an agreement with Janssen Research and Development, LLC with the aim to discover and validate novel tumor and immunological targets and to validate certain therapeutic candidates. The collaboration leverages Resonant's proprietary IMPaCT tumor microenvironment model and target validation platform, and Janssen's industry-leading oncology capabilities to rapidly advance new targets and therapeutic opportunities.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.